The firm expects to validate its test as a triage tool to identify SARS-CoV-2 patients at risk of sepsis and pursue US FDA Emergency Use Authorization.
Roche will have non-exclusive access to SpeeDx's existing tests and technology to enable expansion of diagnostic products for antibiotic resistance in STIs.
The company recently agreed to pay millions to three major insurers under settlement agreements related to allegations over undisclosed past business practices.
The Beijing-based company offers genomics products and services, including PCR instruments and cancer sequencing, and maintains a research center in the US.
Last week, GenomeWeb's readers were most interested in Illumina's announcement that it has received EUA from the FDA for its NGS-based SARS-CoV-2 test.
The test has been developed to run on Illumina's NextSeq 550Dx next-generation sequencing platform and will be prepared for commercial launch in Europe.
Sequences from 20 Neolithic and Iron Age individuals in sub-Saharan Africahelped retrace regional interactions between forager, pastoralist, and farming groups.
KidneyIntelX can be used to report risk assessment results for fast-progressing kidney disease and future kidney failure for patients with chronic kidney disease.
A comparative genomics and machine-learning analysis spanning almost 1,000 viral genomes pointed to two proteins that appear to be altered in SARS-CoV-2 and MERS-CoV.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
